Daratumumab is a monoclonal antibody that specifically targets CD38, a glycoprotein abundantly expressed on the surface of hematopoietic cells, particularly malignant plasma cells such as those found in multiple myeloma. As an IgG1κ antibody, daratumumab binds with high affinity to CD38, triggering a range of immune-mediated cytotoxic effects including apoptosis, antibody-dependent cellular phagocytosis (ADCP), antibody-dependent cellular cytotoxicity (ADCC), and complement-dependent cytotoxicity (CDC). These mechanisms collectively promote the destruction of CD38-expressing tumor cells.
Clinically, daratumumab is used both intravenously and subcutaneously for the treatment of multiple myeloma, either as monotherapy or in combination with other agents. It has a prolonged duration of action, typically administered every 1–4 weeks. Due to its potent immune effects, patients should be monitored for hypersensitivity reactions, neutropenia, thrombocytopenia, and other risks such as interference with blood compatibility testing and embryo-fetal toxicity.
In research and clinical settings, CD38 serves as a reliable biomarker for evaluating disease burden and therapeutic response in multiple myeloma. Daratumumab-based assays and drug monitoring tools are essential for optimizing treatment efficacy and safety, especially when used in complex regimens. Its targeted mechanism makes it a valuable tool in immunotherapy and precision medicine for hematologic malignancies.
This product is manufactured in Turkey by Matriks Biotek.